Association Between Menopause Age and Estradiol-Based Hormone Therapy With Cognitive Performance in Cognitively Normal Women in the CLSA

Tanvi A. Puri, Laura Gravelsins, Madeline Wood Alexander, Andrew J. McGovern, Paula Duarte Guterman, Jennifer S. Rabin, Kelly J. Murphy, Liisa A.M. Galea

Neurology · 2025 · 14 citations · 31 references

DOIFull text

Open access

Concepts

Abstract

BACKGROUND AND OBJECTIVES: Menopause and menopausal hormone therapy (MHT) affect cognition, although existing studies are inconclusive. Age-related declines in executive functions, episodic memory, and prospective memory may be differentially sensitive to menopause age and MHT, due to variations in which brain regions are involved and their estrogen receptor density. Few studies have explored how menopause age and estradiol (E2)-based MHT by administration route affect these domains, a gap that this study addresses. METHODS: This was a cross-sectional observational cohort study using baseline data from the Canadian Longitudinal Study of Aging. We separately examined the associations of age at menopause and E2-based MHT with performance in 3 cognitive domains: episodic memory, prospective memory, and executive functions. Linear regression models were used the test the association between cognitive performance and menopause variables. RESULTS: = 0.345). DISCUSSION: E2-based MHT efficacy depends on the route of administration and cognitive domain, underscoring the importance of considering MHT type. Although we cannot establish causality between menopause age, MHT use, and cognitive outcomes, this work provides clarity to inconsistencies in the literature and informs precision medicine approaches for cognitive aging. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that use of E2-based MHTs was associated with higher episodic memory scores (transdermal E2 preparations) or higher prospective memory scores (oral E2 preparations) in postmenopausal women.

References

31